Presentations on Inovio Biomedical's electroporation-delivered DNA vaccines

Sep 28 2009

Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today it will make multiple presentations at the Vaccine 3^rd Global Congress being held in Singapore October 4^th – 6^th.

Inovio representatives will be making the following presentations regarding electroporation-delivered DNA vaccines:

Delivering on the Promise of DNA Vaccines for HIV and Cancer:
From Bench to Clinical Data
David Weiner, Ph.D., Professor, University of Pennsylvania; Chairman, Scientific Advisory Board, Inovio Biomedical
Plenary Session 5, Novel Vaccines and Delivery Systems
Grand Ballroom
Monday, October 5
13:40

Development of Universal SynCon™ DNA Vaccines for Pandemic and Seasonal Flu
Niranjan Y. Sardesai, Ph.D., Senior VP, R & D, Inovio Biomedical
Breakout Session 1, JSV Sponsored Session and Influenza
Grand Ballroom
Monday, October 5
17:20

The presentations will include progress on programs in Inovio’s pipeline. The congress program consists of invited lectures and presentations selected from submitted abstracts broadly covering vaccine development. The key objectives of the Vaccine 3rd Global Congress are to:

• provide a progressive state-of-the-art report for scientists, governmental authorities and healthcare workers
• accelerate progress in the development of vaccines
• encourage a prophylactic approach to healthcare.